Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowered the price target from $39 to $38.

October 24, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mizuho has maintained a Neutral rating on Apellis Pharmaceuticals and slightly lowered the price target from $39 to $38, indicating a cautious outlook.
The Neutral rating suggests that the analyst does not expect significant upside or downside in the short term. The slight reduction in the price target from $39 to $38 indicates a minor adjustment in expectations, which is not likely to cause a significant impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100